NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis → Prepare for a Recession Unlike Any Other (From American Hartford Gold Group) (Ad) Free XBIT Stock Alerts $6.76 -0.34 (-4.79%) (As of 12:19 PM ET) Add Compare Share Share Today's Range$6.76▼$7.0550-Day Range$6.94▼$9.8952-Week Range$3.51▼$9.96Volume35,880 shsAverage Volume63,755 shsMarket Capitalization$205.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get XBiotech alerts: Email Address Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About XBiotech Stock (NASDAQ:XBIT)XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More XBIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIT Stock News HeadlinesMay 29, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Stock Crosses Below Fifty Day Moving Average of $8.40May 25, 2024 | finance.yahoo.comXBiotech Inc. (XBIT)May 24, 2024 | seekingalpha.comXBiotech: Several Shots On Goal In Big Target Market IndicationsMay 13, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q1 2024April 25, 2024 | finance.yahoo.comXBiotech Inc. (XBIT) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | money.usnews.comXBiotech IncMarch 20, 2024 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersMarch 18, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q4 2023March 8, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechFebruary 17, 2024 | finance.yahoo.comXBIT Mar 2024 5.000 callJanuary 18, 2024 | morningstar.comXBiotech Inc XBITJanuary 8, 2024 | bizjournals.comA top Austin biopharmaceutical company is doubling down on its Austin campusJanuary 4, 2024 | finance.yahoo.comXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusDecember 15, 2023 | msn.comARCT, EHTH and CRTO are among after hour moversDecember 5, 2023 | finance.yahoo.comCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In GrowthNovember 14, 2023 | finanznachrichten.deXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finance.yahoo.comDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisSeptember 26, 2023 | finance.yahoo.comXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeAugust 8, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialJune 30, 2023 | thestreet.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyMay 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesSee More Headlines Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/07/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIT CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees82Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,560,000.00 Net MarginsN/A Pretax Margin-7,401.67% Return on Equity-13.98% Return on Assets-13.38% Debt Debt-to-Equity RatioN/A Current Ratio12.03 Quick Ratio12.03 Sales & Book Value Annual Sales$4.01 million Price / Sales51.35 Cash FlowN/A Price / Cash FlowN/A Book Value$7.19 per share Price / Book0.94Miscellaneous Outstanding Shares30,460,000Free Float20,376,000Market Cap$205.91 million OptionableOptionable Beta1.42 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. John Simard (Age 62)Founder, President, CEO & Chairman Comp: $4.67MDr. Sushma Shivaswamy Ph.D. (Age 46)Chief Scientific Officer Comp: $381.24kMs. Angela Hu (Age 40)Director of Finance, Principal Financial & Accounting Officer and Financial Controller Key CompetitorsFlexion TherapeuticsNASDAQ:FLXNARS PharmaceuticalsNASDAQ:SPRYImmunomeNASDAQ:IMNMABIVAX Société AnonymeNASDAQ:ABVXCentessa PharmaceuticalsNASDAQ:CNTAView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 13,804 shares on 5/10/2024Ownership: 2.940%Empowered Funds LLCBought 4,725 shares on 5/7/2024Ownership: 0.211%View All Institutional Transactions XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed in 2024? XBiotech's stock was trading at $4.00 on January 1st, 2024. Since then, XBIT shares have increased by 69.0% and is now trading at $6.76. View the best growth stocks for 2024 here. When is XBiotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our XBIT earnings forecast. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) announced its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.33) EPS for the quarter. What ETF holds XBiotech's stock? Amplify Treatments, Testing and Advancements ETF holds 7,198 shares of XBIT stock, representing 0.56% of its portfolio. What is John Simard's approval rating as XBiotech's CEO? 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ). When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. Who are XBiotech's major shareholders? XBiotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.94%) and Empowered Funds LLC (0.21%). View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIT) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.